Randomized trialMedical2026

Cannabis to reduce chronic postsurgical pain following total knee arthroplasty: a pilot randomized controlled trial.

Busse J.; Flood B.; Madden K.; Kashir I.; Sadeghirad B.; Atrey A.; Tardif-Theriault C.; Adili A.; Ashoorion V.; Malek M. et al. · Journal of cannabis research · 2026

Research summary

**Background & Methods** This pilot randomized controlled trial enrolled 37 patients scheduled for total knee arthroplasty (TKA) to assess feasibility of a definitive trial evaluating a CBD-dominant cannabis formulation (MPL-001) versus placebo for reducing chronic postsurgical pain. Participants received study medication for 4 weeks preoperatively and 6 weeks postoperatively (extendable to 12 weeks), with 26-week follow-up assessment. **Key Findings** • At 12-week follow-up, moderate-to-severe CPSP was reported by 13% in the MPL-001 arm versus 41% in placebo; at 26 weeks, rates were 14% versus 19% respectively, though differences were not statistically tested due to pilot design. • Preoperative adherence was acceptable (71% took ≥75% of allocated medication), but postoperative adherence declined to 48%; 78% of participants successfully titrated to maximum daily dose. • Study retention was strong at 81% (30/37 completed 26-week follow-up), establishing feasibility for a larger trial. **Dosage & Administration** MPL-001 oral oil drops: up to 2.5 mL/day (125 mg CBD/5 mg THC) administered preoperatively for 4 weeks and postoperatively for 6 weeks, with optional extension to 12 weeks. Formulation contained approximately 50 mg/mL CBD, 2 mg/mL THC, plus minor cannabinoid constituents (CBN, CBC, CBG). **Safety & Adverse Effects** Treatment-related adverse events occurred in 11/19 MPL-001 recipients (18 events total) and 12/18 placebo recipients (19 events total), indicating similar adverse event rates between groups. Gastrointestinal symptoms (nausea and diarrhea) were most common. No serious adverse events requiring study discontinuation were reported. **Evidence Quality** This pilot study is limited by small sample size (n=37), lack of statistical testing due to feasibility focus, high baseline cannabis naivety (81%), and declining postoperative adherence. The study provides proof-of-concept but cannot establish efficacy. Authors acknowledged protocol modifications needed for definitive trials, including expanding recruitment centers and switching from oil drops to capsules to improve adherence. The 26-week follow-up and multicentre design strengthen design quality. Future trials should address adherence barriers and include larger, adequately powered populations.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
Journal of cannabis research
Year
2026
Study type
Randomized trial
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home